Kinea Bio
Kinea Bio is dedicated to accelerating a new era of genetic medicine for neuromuscular diseases. Founded in 2020 by scientific leaders in the neuromuscular disease space, the company focuses on next-generation genetic therapies, leveraging innovative platform technologies such as SIMPLI-GT™, MyoXpress™, BioDrone™, and proprietary myotropic capsids. Their mission is to develop more effective therapeutics for hard-to-cure neuromuscular diseases like Duchenne muscular dystrophy, congenital muscular dystrophy, dysferlinopathies, and myotonic muscular dystrophy, aiming to address high unmet medical needs through advanced gene therapy solutions.
Industries
Nr. of Employees
small (1-50)
Products
Split-intein mediated protein assembly platform
Platform technology that assembles large functional proteins from separate gene segments delivered by genetic vectors to overcome single-vector packaging limits.
Muscle-specific expression cassette library
Collection of engineered muscle-specific enhancer/promoter cassettes enabling graded transgene expression across muscle tissues.
Engineered AAV myotropic capsids
Engineered viral capsids optimized for muscle tropism and reduced hepatic targeting to improve delivery efficiency and safety.
Cell-derived nanovesicle delivery platform
Nanovesicle-based delivery system derived from human cells designed to carry genetic cargo with reduced immunogenicity for repeat dosing regimens.
iPSC-derived neuromuscular disease model suite
Collection of patient-relevant iPSC lines modeling diverse neuromuscular diseases integrated with functional assay readouts for preclinical development.
Split-intein mediated protein assembly platform
Platform technology that assembles large functional proteins from separate gene segments delivered by genetic vectors to overcome single-vector packaging limits.
Muscle-specific expression cassette library
Collection of engineered muscle-specific enhancer/promoter cassettes enabling graded transgene expression across muscle tissues.
Engineered AAV myotropic capsids
Engineered viral capsids optimized for muscle tropism and reduced hepatic targeting to improve delivery efficiency and safety.
Cell-derived nanovesicle delivery platform
Nanovesicle-based delivery system derived from human cells designed to carry genetic cargo with reduced immunogenicity for repeat dosing regimens.
iPSC-derived neuromuscular disease model suite
Collection of patient-relevant iPSC lines modeling diverse neuromuscular diseases integrated with functional assay readouts for preclinical development.
Services
Preclinical IND-enabling study design and execution
Design and execution of IND-enabling preclinical programs in small and large animal models to evaluate gene-transfer efficacy, safety, and durability.
Clinical development strategy and trial operations for gene therapies
Clinical protocol design, site and CRO coordination, medical monitoring, and DSMB interactions for multi-center gene therapy clinical trials.
iPSC disease model creation and functional assay integration
Generation of iPSC lines for neuromuscular disease modeling and integration with functional assay platforms to measure recovery after interventions.
Grant and partnership development
Securing and managing non-dilutive funding and philanthropic partnerships to support translational R&D.
Preclinical IND-enabling study design and execution
Design and execution of IND-enabling preclinical programs in small and large animal models to evaluate gene-transfer efficacy, safety, and durability.
Clinical development strategy and trial operations for gene therapies
Clinical protocol design, site and CRO coordination, medical monitoring, and DSMB interactions for multi-center gene therapy clinical trials.
iPSC disease model creation and functional assay integration
Generation of iPSC lines for neuromuscular disease modeling and integration with functional assay platforms to measure recovery after interventions.
Grant and partnership development
Securing and managing non-dilutive funding and philanthropic partnerships to support translational R&D.
Expertise Areas
- Gene therapy development for neuromuscular diseases
- Non-viral delivery and repeat-dosing strategies
- AAV vector engineering and tropism optimization
- Preclinical translational research and large-animal IND-enabling studies
Key Technologies
- Split-intein protein trans-splicing
- Adeno-associated viral (AAV) vector engineering
- Cell-derived nanovesicle delivery
- Muscle-specific enhancer/promoter expression cassettes (MSECs)